Aggressive Therapy With Intravenous Abciximab and Intra-Arterial rtPA and Additional PTA/Stenting Improves Clinical Outcome in Acute Vertebrobasilar Occlusion: Combined Local Fibrinolysis and Intravenous Abciximab in Acute Vertebrobasilar Stroke Treatment (FAST) Results of a Multicenter Study

Background and Purpose— A combined therapy of local recombinant tissue plasminogen activator (rtPA) fibrinolysis and intravenous Abciximab platelet inhibition with additional percutaneous transluminal angioplasty (PTA)/stenting may improve recanalization and neurological outcome in patients with acute vertebrobasilar occlusion. Methods Combined FAST therapy consisted on intravenous bolus of Abciximab (0.25 mg/kg) followed by a 12-hour infusion therapy (0.125 &mgr;g/kg per minute) and low-dose intra-arterial rtPA (median dosage: 20 mg, FAST cohort: N=47). The results were compared with a retrospective cohort, treated by intraarterial rtPA monotherapy (median dosage: 40 mg, rtPA cohort, N=41). Additional PTA/stenting was performed in case of severe residual stenosis. Recanalization success was classified according to the Trials in Myocardial Infarction (TIMI) criteria: TIMI0/1, failed recanalization; TIMI2/3, successful recanalization. Bleeding complications were evaluated according to severe extracerebral hemorrhage (ECH), asymptomatic intracerebral hemorrhage (AIH), and symptomatic intracerebral hemorrhage (SIH). Results— Overall bleeding rate was higher under the combined therapy, but the SIH rate did not differ (FAST versus rtPA: ECH, 3% versus 0%; AIH, 32% versus 22%; SIH 13% versus 12%). Additional PTA/stenting was performed in 14 (FAST) versus 5 (rtPA) patients. TIMI2/3 recanalization rate was similar (FAST, 72%; rtPA, 68%), but TIMI3 rate was remarkably higher under combined therapy (FAST, 45%; rtPA, N=22%). Neurologic outcome appeared better under combined therapy (FAST versus rtPA: favorable outcome rate: 34% versus 17%) with a significantly lower mortality rate (FAST versus rtPA: 38% versus 68%; P=0.006). These results were consistent for embolic and atherothrombotic occlusions. Conclusion Combined therapy of intravenous Abciximab and half dose intra-arterial rtPA with additional PTA/stenting appears to improve neurologic outcome in acute vertebrobasilar occlusion despite an increase of overall bleeding complications.

[1]  S. Wisniewski,et al.  Factors affecting survival rates for acute vertebrobasilar artery occlusions treated with intra-arterial thrombolytic therapy: a meta-analytical approach. , 1999, Neurosurgery.

[2]  J. Heo,et al.  Rescue treatment with abciximab in acute ischemic stroke , 2001, Neurology.

[3]  A. Alexandrov,et al.  Deterioration following improvement with tPA therapy: Carotid thrombosis and reocclusion , 2001, Neurology.

[4]  A M Norbash,et al.  Rheolytic thrombectomy of the occluded internal carotid artery in the setting of acute ischemic stroke. , 2001, AJNR. American journal of neuroradiology.

[5]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[6]  A. Qureshi,et al.  Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke. , 2004, AJNR. American journal of neuroradiology.

[7]  R. Adams,et al.  Occlusion of the basilar artery; a clinical and pathological study. , 1946, Brain : a journal of neurology.

[8]  M. Kaste,et al.  Long-term outcome after intravenous thrombolysis of basilar artery occlusion. , 2004, JAMA.

[9]  E. Connolly,et al.  Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. , 1998, The Journal of clinical investigation.

[10]  C. Archer,et al.  Basilar Artery Occlusion Clinical and Radiological Correlation , 1977, Stroke.

[11]  W. Hacke,et al.  [Local fibrinolysis in basilar artery thrombosis (author's transl)]. , 2008, Deutsche medizinische Wochenschrift.

[12]  C. Groden,et al.  Endovascular Therapy of Acute Vertebrobasilar Occlusion: Early Treatment Onset as the Most Important Factor , 2002, Cerebrovascular Diseases.

[13]  M. Chopp,et al.  Adjuvant Treatment With a Glycoprotein IIb/IIIa Receptor Inhibitor Increases the Therapeutic Window for Low-Dose Tissue Plasminogen Activator Administration in a Rat Model of Embolic Stroke , 2003, Circulation.

[14]  D. Moliterno,et al.  Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor. , 1997, AJNR. American journal of neuroradiology.

[15]  Fernando Vinuela,et al.  MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia , 2004, Stroke.

[16]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[17]  R. Seitz,et al.  Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion , 2004, Stroke.

[18]  R. Becker.  Dynamics of coronary thrombolysis and reocclusion , 1997, Clinical cardiology.

[19]  Gregory,et al.  Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. , 1988, Stroke.

[20]  G. Thomalla,et al.  Acute Basilar Artery Occlusion Treated With Combined Intravenous Abciximab and Intra-arterial Tissue Plasminogen Activator: Report of 3 Cases , 2002, Stroke.

[21]  R. Seitz,et al.  Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases. , 2001, Radiology.

[22]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. , 1999, Circulation.